Company Shares of Second Sight Medical Products (NASDAQ:EYES) Rally 16.33%

Second Sight Medical Products (NASDAQ:EYES) has been under a strong bear grip, hence the stock is down -0.86% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 14.86% in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 16.33% in the last 1 week, and is up 0.74% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The company shares have dropped -70.94% from its 1 Year high price. On Jul 15, 2015, the shares registered one year high at $15.28 and the one year low was seen on Jun 27, 2016. The 50-Day Moving Average price is $3.78 and the 200 Day Moving Average price is recorded at $4.63.

The stock has recorded a 20-day Moving Average of 9.63% and the 50-Day Moving Average is 3.26%.


Second Sight Medical Products (NASDAQ:EYES): On Fridays trading session , Opening price of the stock was $4.13 with an intraday high of $4.2. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $3.96. However, the stock managed to close at $4.06, a loss of 0.98% for the day. On the previous day, the stock had closed at $4.1. The total traded volume of the day was 691,641 shares.

In an insider trading activity, The Securities and Exchange Commission has divulged that Randolph Edward David, officer (VP of Manufacturing) of Second Sight Medical Products Inc, had unloaded 5,104 shares at an average price of $4.01 in a transaction dated on June 3, 2016. The total value of the transaction was worth $20,467.

Second Sight Medical Products, Inc. is a medical device company that develops, manufactures and markets implantable visual prosthetics to restore some functional vision to blind patients. The Companys product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision that normally sighted people have. The Argus II Retinal Prosthesis System consists of an implant, a small portable computer and a pair of glasses with a miniature video camera. The Argus II system received Conformite Europeenne (CE) Mark approval for marketing and sales in the European Union (EU), and approval by the United States Food and Drug Administration (FDA) for marketing and sales in the United State. The Company also markets the Argus II system in Canada, Turkey, and at one medical center in Saudi Arabia.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.